Company Profile

Anchored in work undertaken by the principal during his achieving his PhD at Boston University, HelixBind is structured around improving diagnosis and management of invasive infections with a particular focus on bloodstream infections and sepsis The firm's proprietary Resistance and Pathogen Identification (RaPID) platform provides rapid detection and unequivocal identification of bloodstream infections, direct from a whole blood specimen and without the need for blood culture. RaPID results allow physicians quickly to select the optimal antimicrobial intervention, targeted for the specific infection, and to monitor the effectiveness of that treatment throughout care. A biomedical engineering company working in the detection and identification of infectious pathogens using genomic information, the company uses the known genomic information regarding certain strains of pathogens to create detectable genomic ‘tags’ specific to the DNA of each strain.The firm's proprietary RaPID platform provides culture-free characterization of bacterial and fungal pathogens and their resistance mechanisms direct from patient specimens, enabling clinicians to quickly diagnosis and monitor infection progression to ensure prompt and appropriate care.